Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer
Condition: Bladder Cancer; Breast Cancer; Colorectal Cancer; Head and Neck Cancer; Lung Cancer; Lymphoma; Prostate Cancer; Testicular Germ Cell Tumor; Tobacco Use Disorder; Unspecified Adult Solid Tumor, Protocol Specific
MeSH terms: Lymphoma; Neoplasms; Breast Neoplasms; Lung Neoplasms; Prostatic Neoplasms; Urinary Bladder Neoplasms; Neoplasms, Germ Cell and Embryonal; Tobacco Use Disorder
Study type: Interventional

Summary: 
      RATIONALE: Physician-initiated smoking cessation strategies may be effective in getting
      early-stage cancer patients to quit smoking.

      PURPOSE: Randomized clinical trial to compare the effectiveness of a physician-initiated
      stop-smoking program with the usual care for patients receiving treatment for early-stage
      cancer.
    

Detailed description: 
      OBJECTIVES:

        -  Compare the efficacy of brief physician-initiated smoking cessation strategies vs usual
           care in patients with early stage cancer who are undergoing treatment in clinical
           oncology settings.

        -  Compare the sociodemographic, smoking history, and health status correlates of smoking
           cessation in patients treated with these regimens.

        -  Determine the feasibility of conducting a cancer prevention and control study in a
           cooperative group setting by monitoring adherence to the smoking-cessation strategies.

      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to
      center. Patients are randomized to 1 of 2 treatment arms.

        -  Arm I: Patients receive usual care (no special intervention).

        -  Arm II: Patients receive smoking-cessation therapy based on the 4-step intervention plan
           in the "Manual for Physicians" published by the National Cancer Institute. The smoking
           cessation coordinator and physician provide self-quitting advice and support to the
           patient via counseling, self-help materials, and referral to a smoking cessation
           counselor at the Cancer Information Service (CIS). Patients receive nicotine
           replacement, if indicated. Patients who express an interest in more intensive treatment
           are referred to local American Cancer Society or American Lung Association clinics
           and/or advised to call the CIS for additional local program referrals.

      All patients are followed at 6 and 12 months. Patients who report that they are still smoking
      and interested in help to quit smoking at the 12-month follow-up interview are encouraged to
      return to their physicians and contact the CIS for additional help quitting or for a referral
      to more intensive or specialized treatments in their area.

      PROJECTED ACCRUAL: A total of 494 patients will be accrued for this study.
    

Intervention name(s): nicotine; Usual Care
Intervention type(s): Drug; Behavioral
Intervention MeSH terms: Nicotine
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Other
Keywords: stage I adult Hodgkin lymphoma; angioimmunoblastic T-cell lymphoma; stage II adult Hodgkin lymphoma; stage III adult Hodgkin lymphoma; stage IV adult Hodgkin lymphoma; stage I colon cancer; stage II colon cancer; stage I breast cancer; AIDS-related peripheral/systemic lymphoma; AIDS-related primary CNS lymphoma; anaplastic large cell lymphoma; contiguous stage II adult diffuse large cell lymphoma; contiguous stage II adult diffuse mixed cell lymphoma; contiguous stage II adult diffuse small cleaved cell lymphoma; contiguous stage II adult Burkitt lymphoma; contiguous stage II adult immunoblastic large cell lymphoma; contiguous stage II adult lymphoblastic lymphoma; contiguous stage II grade 1 follicular lymphoma; contiguous stage II grade 2 follicular lymphoma; contiguous stage II grade 3 follicular lymphoma; contiguous stage II mantle cell lymphoma; intraocular lymphoma; limited stage small cell lung cancer; noncontiguous stage II adult diffuse large cell lymphoma; noncontiguous stage II adult diffuse mixed cell lymphoma; noncontiguous stage II adult diffuse small cleaved cell lymphoma; noncontiguous stage II adult Burkitt lymphoma; noncontiguous stage II adult immunoblastic large cell lymphoma; noncontiguous stage II adult lymphoblastic lymphoma; noncontiguous stage II grade 1 follicular lymphoma; noncontiguous stage II grade 2 follicular lymphoma; noncontiguous stage II grade 3 follicular lymphoma; noncontiguous stage II mantle cell lymphoma; primary central nervous system lymphoma; tobacco use disorder; stage I adenoid cystic carcinoma of the oral cavity; stage I adult T-cell leukemia/lymphoma; stage I adult diffuse large cell lymphoma; stage I adult diffuse mixed cell lymphoma; stage I adult diffuse small cleaved cell lymphoma; stage I adult Burkitt lymphoma; stage I adult immunoblastic large cell lymphoma; stage I adult lymphoblastic lymphoma; stage I basal cell carcinoma of the lip; stage I cutaneous T-cell non-Hodgkin lymphoma; stage I esthesioneuroblastoma of the paranasal sinus and nasal cavity; stage I grade 1 follicular lymphoma; stage I grade 2 follicular lymphoma; stage I grade 3 follicular lymphoma; stage I inverted papilloma of the paranasal sinus and nasal cavity; stage I lymphoepithelioma of the nasopharynx; stage I lymphoepithelioma of the oropharynx; stage I mantle cell lymphoma; stage I midline lethal granuloma of the paranasal sinus and nasal cavity; stage I mucoepidermoid carcinoma of the oral cavity; stage I mycosis fungoides/Sezary syndrome; stage I non-small cell lung cancer; stage I prostate cancer; stage I rectal cancer; stage I squamous cell carcinoma of the hypopharynx; stage I squamous cell carcinoma of the larynx; stage I squamous cell carcinoma of the lip and oral cavity; stage I squamous cell carcinoma of the nasopharynx; stage I squamous cell carcinoma of the oropharynx; stage I squamous cell carcinoma of the paranasal sinus and nasal cavity; stage I malignant testicular germ cell tumor; stage I verrucous carcinoma of the larynx; stage I verrucous carcinoma of the oral cavity; stage II adult T-cell leukemia/lymphoma; stage II adenoid cystic carcinoma of the oral cavity; stage II basal cell carcinoma of the lip; stage II bladder cancer; stage II breast cancer; stage II cutaneous T-cell non-Hodgkin lymphoma; stage II esthesioneuroblastoma of the paranasal sinus and nasal cavity; stage II inverted papilloma of the paranasal sinus and nasal cavity; stage II lymphoepithelioma of the nasopharynx; stage II lymphoepithelioma of the oropharynx; stage II midline lethal granuloma of the paranasal sinus and nasal cavity; stage II mucoepidermoid carcinoma of the oral cavity; stage II mycosis fungoides/Sezary syndrome; stage I bladder cancer; stage II non-small cell lung cancer; stage II prostate cancer; stage II rectal cancer; stage II squamous cell carcinoma of the hypopharynx; stage II squamous cell carcinoma of the larynx; stage II squamous cell carcinoma of the lip and oral cavity; stage II squamous cell carcinoma of the nasopharynx; stage II squamous cell carcinoma of the oropharynx; stage II squamous cell carcinoma of the paranasal sinus and nasal cavity; stage II malignant testicular germ cell tumor; stage II verrucous carcinoma of the larynx; stage II verrucous carcinoma of the oral cavity; stage III adult T-cell leukemia/lymphoma; stage III adult diffuse large cell lymphoma; stage III adult diffuse mixed cell lymphoma; stage III adult diffuse small cleaved cell lymphoma; stage III adult Burkitt lymphoma; stage III adult immunoblastic large cell lymphoma; stage III adult lymphoblastic lymphoma; stage III cutaneous T-cell non-Hodgkin lymphoma; stage III grade 1 follicular lymphoma; stage III grade 2 follicular lymphoma; stage III grade 3 follicular lymphoma; stage III mantle cell lymphoma; stage III mycosis fungoides/Sezary syndrome; stage III prostate cancer; stage III malignant testicular germ cell tumor; stage IIIA breast cancer; stage IIIB breast cancer; stage IV adult T-cell leukemia/lymphoma; stage IV adult diffuse large cell lymphoma; stage IV adult diffuse mixed cell lymphoma; stage IV adult diffuse small cleaved cell lymphoma; stage IV adult Burkitt lymphoma; stage IV adult immunoblastic large cell lymphoma; stage IV adult lymphoblastic lymphoma; stage IV breast cancer; stage IV cutaneous T-cell non-Hodgkin lymphoma; stage IV grade 1 follicular lymphoma; stage IV grade 2 follicular lymphoma; stage IV grade 3 follicular lymphoma; stage IV mantle cell lymphoma; stage IV mycosis fungoides/Sezary syndrome; stage IV prostate cancer; unspecified adult solid tumor, protocol specific; contiguous stage II marginal zone lymphoma; contiguous stage II small lymphocytic lymphoma; noncontiguous stage II small lymphocytic lymphoma; noncontiguous stage II marginal zone lymphoma; stage I marginal zone lymphoma; stage I small lymphocytic lymphoma; stage III small lymphocytic lymphoma; stage III marginal zone lymphoma; stage IV small lymphocytic lymphoma; stage IV marginal zone lymphoma; extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue; nodal marginal zone B-cell lymphoma; splenic marginal zone lymphoma